Oral edaravone treatment of acute ischemic stroke (IMAGE)

Science China Press

Oral edaravone treatment of acute ischemic stroke

Caption

Modified Rankin Scale (mRS) scores at 90 days in the intention-to-treat population. TTYP01 demonstrated a favorable shift toward better functional outcomes, with significantly more patients achieving mRS 0–1 compared to placebo.

Credit

ERASE-STROKE Investigators

Usage Restrictions

use with credit.

License

Original content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.